Showing 10 news articles (Filtered on year "2014", language "English")
2014-12-22
Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR) announced that MIV-802 has been selected as a candidate drug (CD) from its hepatitis C virus (HCV) nucleotide polymerase inhibitor project for the treatment of HCV infection, and is entering non-clinical development
2014-11-20
Voluntary redemption programmeThe extraordinary general meeting in Medivir Aktiebolag (publ) on 20 November 2014 resolved, in accordance with the board of directors' proposal, on a voluntary redemption programme comprising reduction of the statutory reserve, reduction of the share capital
2014-11-20
Financial summary for the third quarter* July to September 2014 (2013) Net turnover totalled SEK 617.8 million (SEK 80.2 m), SEK 516.4 million (SEK 0 m) of which comprised royalties for simeprevir. Revenues from Medivir’s own pharmaceutical sales totalled SEK 100.8 million (SEK 36.6 m), SEK 61.6
2014-11-06
-Expanded indication includes both treatment-naïve and treatment-experienced adult patients with or without cirrhosis-
2014-10-30
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company has entered into an agreement with Swedish county councils regarding the treatment of hepatitis C with Olysio® (simeprevir). The Dental and Pharmaceutical Benefits Agency (TLV) has concluded that treatment with Olysio®
2014-10-28
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced that its Nomination Committee has been appointed. According to an AGM resolution, the Nomination Committee for the Annual General Meeting 2015 should consist of representatives for the three largest ranked shareholders, as of
2014-10-23
The shareholders in Medivir AB are hereby summoned to the extraordinary general meeting on Thursday 20 November 2014 at 10 a.m. at the conference center Nio Rum, Hamngatan 2, Stockholm, Sweden. Participation Shareholders who wish to participate in the meeting must (a) be recorded in the share register
2014-10-16
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces the intention of launching a voluntary share redemption program. “The successful market introduction of simeprevir has led to a very strong cash position and profitability for Medivir within a short time frame. Based on our strategy
2014-10-14
Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to 796 MUSD, of which 671 MUSD were sales in the USA. Medivir’s royalties based on sales for the third quarter are calculated from the highest royalty tier and currency
2014-10-10
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that its partner Janssen recently initiated patient enrolment in a phase II study called IMPACT. This study evaluates the efficacy, safety and pharmacokinetics of the NS3/4A protease inhibitor simeprevir administered once daily in combination